Means, standard deviations, ranges, and frequencies for the sample’s demographic characteristics. by Yael Fogel (11883343)

Deterministic result of the base-case analysis. by Sudewi Mukaromah Khoirunnisa (15288505)

“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”

Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)

Base-case results based on evidence from randomized controlled trials (means and ranges). The comparator is no intervention. by Afschin Gandjour (342184)

Base-case results (deterministic analysis). by Robert Hodgson (2026294)

Base-case results: Probabilistic analysis. by Robert Hodgson (2026294)

Estimated mean values for light interception. by Torsten Schober (20485754)

“…In the context of standardized production, we therefore advocate high-density production systems that increase the proportion of desired inflorescence fractions from upper canopy layers.…”

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Significant demographic factors associated with the usefulness of an early warning to take timely preventive action. by Rafdzah Zaki (161810)

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

“…By comparing samples from NAFLD patients and healthy controls, we identified 1,770 significant DEGs, with 1,073 being upregulated and 697 downregulated. …”

Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

“…Shaded regions correspond to the standard error of the mean and dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs. …”

Base-case results. by Mingxi Xie (19812594)

“…Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. …”

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Base-case analysis. by Akiko Kowada (14659965)

“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”

Effects of Remote Ischemic Preconditioning on Decreasing Troponin Release in Patients Not Taking Sulfonylureas After Cardiac Surgery – A Meta-Analysis by Xiaotong Wang (276499)